Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

DMONICKASEDESIGN

Financiado

Cerrado

Safer gene repair and targeting based on the monomeric meganuclease I DmoI by de...

Safer gene repair and targeting based on the monomeric meganuclease I DmoI by design of homologous recombination inducing nickase activity An important aspect of cancer therapy is the specificity of the treatment. Significant progress has been made in drug design. However, gene therapy by direct targeting of oncogenes has not yet met equal success. Among the most val... ver más

31/03/2013

FUNDACION SECTOR P...

155K€

Presupuesto del proyecto: 155K€

Líder del proyecto

FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIO... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 18M€

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2013-03-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

FUNDACION SECTOR PUBLICO EST...

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SMARTBREAKER Rational designing of new meganucleases as molecular scissor... 75K€ Cerrado

BFU2013-50400-EXP BUSQUEDA DE HOMOLOGIA ASISTIDA POR EL ARN MENSAJERO 36K€ Cerrado

SUPERSIST Towards clinical translation of new gene targeting technolog... 8M€ Cerrado

CNS2023-143939 Biología molecular y celular 200K€ Cerrado

BFU2017-83794-P BIOFISICA DE MOLECULA UNICA PARA EL ESTUDIO DE MAQUINAS PROT... 235K€ Cerrado

coDNAres Regulation of DNA resection DNA repair and genomic stabilit... 161K€ Cerrado

Líder del proyecto

FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIO... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 18M€

Presupuesto del proyecto 155K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto An important aspect of cancer therapy is the specificity of the treatment. Significant progress has been made in drug design. However, gene therapy by direct targeting of oncogenes has not yet met equal success. Among the most valuable tools are meganucleases, also known as homing endonucleases (HE). These enzymes recognize and cleave long (around 20bp) DNA sequences and have been shown to induce gene repair in vivo efficiently. The mechanism involves induction of homologous recombination (HR) by creating a double strand break (DSB) of DNA. HEs also have the significant advantage of being amenable to redesign for new target sequences. Applications have been demonstrated, for example, in the treatment of xeroderma pigmentosum, a condition associated with skin carcinomas. Unfortunately, inducing HR by DSB tends to produce genetic instabilities. A safer alternative would be to use single-strand-cleaving enzymes (nickases). However, this must be done retaining sequence specificity, a property unavailable in natural enzymes. Consequently, engineering is necessary. A promising candidate for redesign is the monomeric HE I-DmoI, but details of the mechanism, namely the role of metals in the active site and the precise timing of strand cleavage, must still be unraveled. X-ray and mutagenesis experiments performed at CNIO provided significant, although incomplete, evidence on those crucial aspects. Experimentally-supported theory and computational modeling can help clarify remaining incognitas, such as the strand preference of the enzyme. We will use state-of-the-art computational methods (ab-initio molecular dynamics, hybrid Quantum Mechanics/Molecular Mechanics and molecular modeling), to gain insight into aspects of the mechanism not seen in experiments, including the timing of strand cleavage. This knowledge could eventually lead to the design of a more effective and specific HEs to be used in gene therapy of skin cancer, and hopefully of other types.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores